Cyclopharm seeks ASX quotation for over 5.2 million new shares

Cyclopharm Limited ( (AU:CYC) ) has provided an announcement.

Cyclopharm Limited has applied for quotation on the ASX of 5,263,158 ordinary fully paid shares, with an issue date of 20 April 2026. The new securities, issued under previously announced transactions, will expand the company’s listed share capital and may enhance its liquidity and visibility among investors.

The application formalises the admission of these additional shares to trading on the exchange, aligning Cyclopharm’s capital structure with earlier market disclosures. The move could support future capital-raising flexibility and signals continued engagement with the ASX market for funding and growth initiatives.

The most recent analyst rating on (AU:CYC) stock is a Buy with a A$1.50 price target. To see the full list of analyst forecasts on Cyclopharm Limited stock, see the AU:CYC Stock Forecast page.

More about Cyclopharm Limited

Cyclopharm Limited is an Australia-based company listed on the ASX under the code CYC. It operates in the healthcare sector and issues ordinary fully paid shares as its primary equity securities for investors in the Australian capital markets.

Average Trading Volume: 145,437

Technical Sentiment Signal: Sell

Current Market Cap: A$93.62M

For detailed information about CYC stock, go to TipRanks’ Stock Analysis page.